Unisys Innovation Program Announces the Winners of Its 16th Annual Competition
Top three teams recognized for ideas to create sustainable electric mobility, tumor…
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
The TUXEDO-3 trial is the first study to evaluate the intracranial and…
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to…
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit…
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest…
Bio-Path Holdings Provides Key Clinical Updates
February 13, 2025 08:00 ET | Source: Bio-Path Holdings, Inc. First Solid…
Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025…
Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics…
Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar…
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…